Stimulants and Other ADHD Medicines

2020 ◽  
pp. 231-266
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Eating Disorder ◽  
Clinical Characteristics ◽  
Mechanisms Of Action ◽  
Black Box ◽  
Brand Names ◽  
Clinical Use ◽  
Childbearing Age ◽  
Hyperactivity Disorder ◽  
Medical Disorders ◽  
Black Box Warnings

The chapter on adult attention-deficit/hyperactivity disorder (ADHD) medicines discusses and reviews the use of psychostimulants (such as methylphenidate and amphetamines), and nonstimulants (such as atomoxetine, guanfacine, and clonidine). It reviews their mechanisms of action, clinical characteristics, potential medication interactions, and adverse effects. It further reviews stimulants’ risk of misuse and dependence. The chapter also briefly discusses complementary and alternative pharmacotherapies. It includes an in-depth review of the clinical use of these medications for ADHD (particularly in college students) and for other psychiatric disorders (such as binge-eating disorder) and other medical disorders. It also discusses the use of ADHD medicines in women of childbearing age, notably for pregnancy and breastfeeding considerations. Finally, the chapter includes a table of ADHD medicines that includes each medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and Food and Drug Administration indications.

Antipsychotics

2020 ◽  
pp. 121-184
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Clinical Characteristics ◽  
First Generation ◽  
Black Box ◽  
Brand Names ◽  
Clinical Use ◽  
Childbearing Age ◽  
Medical Disorders ◽  
Second Generation Antipsychotics ◽  
Black Box Warnings ◽  
Potential Risks

The chapter on antipsychotics discusses and reviews the use of first-generation antipsychotics, including haloperidol and chlorpromazine, as well as the use of second-generation antipsychotics, including risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, clozapine, paliperidone, iloperidone, asenapine, lurasidone, brexpiprazole, and cariprazine. Pimavanserin is also discussed. The chapter reviews each medication’s mechanism of action, clinical characteristics, potential medication interactions, and potential risks including neuroleptic side effects such as acute dystonias, parkinsonian symptoms, akathisia, and tardive dyskinesia. Metabolic syndrome (which includes risks of weight gain, hyperglycemia, and hyperlipidemias) and cardiac risks are also discussed. The chapter also briefly discusses complementary and alternative pharmacotherapies. It then provides an in-depth review of the clinical use of antipsychotics for psychotic and behavioral disorders, as well as for other nonpsychotic psychiatric and medical disorders. It also discusses the use of antipsychotics in women of childbearing age, notably in regard to pregnancy and breastfeeding considerations. Finally, the chapter includes a table of antipsychotics that includes each medication’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and Food and Drug Administration indications.

Anti-Anxiety Medicines and Hypnotics

2020 ◽  
pp. 85-120
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Adverse Effects ◽  
Clinical Characteristics ◽  
Food And Drug Administration ◽  
Mechanisms Of Action ◽  
Black Box ◽  
Abuse Potential ◽  
Brand Names ◽  
Clinical Use ◽  
Childbearing Age ◽  
Black Box Warnings

The chapter on anti-anxiety medicines and hypnotics discusses and reviews the use of benzodiazepines and barbiturates, medicines without abuse potential used for the treatments of anxiety (such as buspirone, propranolol, clonidine, prazosin, hydroxyzine, pregabalin, gabapentin, and quetiapine), as well as newer hypnotics including “z-drugs” considered for insomnia and sleep. It reviews their mechanisms of action, clinical characteristics, potential medication interactions, adverse effects, as well as their risks of dependence and misuse. It also briefly discusses complementary and alternative pharmacotherapies such as melatonin and cannabidiol. The chapter includes an in-depth discussion of the clinical use of these medications for anxiety and insomnia. It also discusses the use of anxiolytics in women of childbearing age, notably for pregnancy and breastfeeding considerations. Finally, the chapter includes a table of commonly used anti-anxiety medicines and hypnotics that includes each medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings and Food and Drug Administration indications.

Antidepressants

2020 ◽  
pp. 15-84
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Clinical Characteristics ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Unipolar Depression ◽  
Black Box ◽  
Brand Names ◽  
Clinical Use ◽  
Childbearing Age ◽  
Medical Disorders ◽  
Black Box Warnings ◽  
Norepinephrine Reuptake

The chapter on antidepressants discusses and reviews the use of tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors, as well as bupropion, mirtazapine, nefazodone, trazodone, and the newer antidepressants vilazodone and vortioxetine. It reviews each medication’s mechanism of action, clinical characteristics, potential medication interactions, adverse effects, and other risks. The chapter also reviews emerging pharmacotherapies such as ketamine, esketamine, and brexanolone. It also briefly discusses complementary and alternative pharmacotherapies. The chapter includes an in-depth discussion of the clinical use of antidepressants for the treatment of unipolar depression and other psychiatric and medical disorders. It also discusses the use of antidepressants in women of childbearing age, notably in regards to pregnancy and breastfeeding considerations. Finally, each chapter includes a table of antidepressants that includes each medication’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and FDA indications.

Mood Stabilizers

2020 ◽  
pp. 185-230
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Clinical Characteristics ◽  
Bipolar Depression ◽  
Black Box ◽  
Brand Names ◽  
Mood Stabilizers ◽  
Clinical Use ◽  
Omega 3 ◽  
Childbearing Age ◽  
Second Generation Antipsychotics ◽  
Black Box Warnings

The chapter on mood stabilizers discusses and reviews the use of available treatments for bipolar disorder, including lithium, selected anticonvulsants (such as valproate, carbamazepine, oxcarbazepine, and lamotrigine) and second-generation antipsychotics. It reviews each medication’s mechanism of action, clinical characteristics, potential medication interactions, and adverse effects. The chapter also reviews emerging pharmacotherapies such as the use of ketamine. It also briefly discusses complementary and alternative pharmacotherapies and the use of omega-3 fatty acids. The chapter includes an in-depth review of the clinical use of the previously listed medications for bipolar depression, mania, mixed episodes, and bipolar maintenance. It also reviews the risks of using antidepressants for bipolar depression. It also discusses the use of mood stabilizers in women of childbearing age, notably for pregnancy and breastfeeding considerations. Finally, the chapter includes a table of mood stabilizers that includes each medication’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings and Food and Drug Administration indications.

Treatments for Substance Use Disorders

2020 ◽  
pp. 267-324
Author(s):  
Arash Ansari ◽  
David N. Osser
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Clinical Characteristics ◽  
Black Box ◽  
Brand Names ◽  
Opioid Use ◽  
Childbearing Age ◽  
Black Box Warnings ◽  
Amphetamine Use ◽  
Opioid Use Disorders

The chapter on treatments for substance use disorders discusses and reviews the use of medication-assisted treatments with (a) methadone, buprenorphine/naloxone, and naltrexone for opioid use disorders; (b) disulfiram, acamprosate, naltrexone, and several off-label medications for alcohol use disorders; and (c) nicotine replacement therapies, bupropion, and varenicline for tobacco use disorders. The chapter reviews the mechanisms of action, clinical characteristics, potential medication interactions, and adverse effects of these medications, followed by an in-depth discussion of their clinical use in these disorders. The chapter also briefly reviews several non-Food and Drug Administration (FDA)-approved medicines studied for cocaine, cannabis, and amphetamine use disorders. It also briefly discusses complementary and alternative pharmacotherapies, such as the use of cannabinoids. It also discusses the use of these medicines in women of childbearing age, notably for pregnancy and breastfeeding considerations. Finally, the chapter includes a table of approved substance use disorder medicines that includes each medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and FDA indications.

Psychopharmacology

2020 ◽  
Author(s):  
Arash Ansari ◽  
David Osser
Keyword(s):  
Primary Care Physicians ◽  
Brand Names ◽  
Mood Stabilizers ◽  
Therapeutic Effects ◽  
Childbearing Age ◽  
Clinical Nurse Specialists ◽  
Therapeutic Uses ◽  
Emerging Therapies ◽  
Black Box Warnings ◽  
Short And Long Term

Psychopharmacology: A Concise Overview, 3rd Edition discusses and reviews currently available psychiatric medications and their evidence-supported use in current clinical practice. It discusses the therapeutic uses of antidepressants, anti-anxiety medications, antipsychotics, mood stabilizers, stimulants, and other medications for attention-deficit/hyperactivity disorder (ADHD), as well as medicines for substance use disorders. It reviews the medications’ mechanisms of action, therapeutic effects, potential drug–drug interactions and short- and long-term adverse effects and risks. It includes sections on complementary and alternative pharmacotherapies as well as on emerging therapies. Every chapter includes an in-depth discussion of the clinical use of the reviewed classes of medications as they are used for the alleviation of their target psychiatric disorders, such as depression, anxiety disorders, schizophrenia, bipolar disorder, ADHD, and opioid, alcohol, and tobacco use disorders. Treatment challenges and controversies are reviewed. In addition, each chapter discusses the use of these medications in other psychiatric and medical conditions as well. Each chapter also discusses the use of these medications in women of childbearing age, especially in light of pregnancy and breastfeeding considerations. Finally, each chapter includes a table that provides each reviewed medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and Food and Drug Administration indications. This book provides a concise and accessible overview that would be helpful to medical students, psychiatric residents, psychiatrists, primary care physicians, clinical nurse specialists, and nonmedical mental health practitioners.

The Influence of FDA Advisory Information and Black Box Warnings on Consumer Use of Prescription Antidepressants

2008 ◽  
Author(s):  
Kristy Parkinson ◽  
Joseph Price ◽  
Kosali Ilayperuma Simon ◽  
Sharon L. Tennyson
Keyword(s):  
Black Box ◽  
Black Box Warnings

Twitter Analysis of the Nonmedical Use and Side Effects of Methylphenidate, and User Sentiment about the Drug (Preprint)

2019 ◽  
Author(s):  
Jungu Kim ◽  
Su Cheol Kim ◽  
Jaegwon Jeong ◽  
Myeong Gyu Kim
Keyword(s):  
Side Effects ◽  
Social Networking ◽  
Brand Names ◽  
Social Networking Services ◽  
Hyperactivity Disorder ◽  
Search Terms ◽  
Nonmedical Use ◽  
Twitter Analysis ◽  
Sentiment Score ◽  
The Cost

BACKGROUND Methylphenidate, a stimulant used to treat attention deficit hyperactivity disorder (ADHD), has the potential for nonmedical uses such as study and recreation. In the era of active use of social networking services (SNSs), experience with the nonmedical use or side effects of methylphenidate might be shared on Twitter. OBJECTIVE To analyze monthly tweets about methylphenidate, its nonmedical use and side effects, and user sentiments about methylphenidate. METHODS Tweets mentioning methylphenidate from August 2018 to July 2019 were collected using search terms for methylphenidate and its brand names. Only tweets written in English were included. The monthly number of tweets about methylphenidate and the number of tweets containing keywords related to the nonmedical use and side effects of methylphenidate were analyzed. Precision was calculated as the number of true nonmedical use or side effects divided by the number of tweets containing each keywords. Sentiment analysis was conducted using the text and emoji in tweets, and tweets were categorized as very negative (less than -3), negative (-3 to -1), neutral (0), positive (1 to 3), or very positive (more than 3), depending on the sentiment score. RESULTS A total of 4,169 tweets were ultimately selected for analysis. The number of tweets per month was lowest in August (n=264) and highest in May (n=435). There were 292 (7.0%) tweets about nonmedical uses of methylphenidate. Among those, 200 (4.8%) described use for studying, and 15 (0.4%) described use for recreation. In 91 (2.2%) tweets, snorting methylphenidate was mentioned. Side effects of methylphenidate, mainly poor appetite (n=74, 1.8%) and insomnia (n=54, 1.3%), were reported in 316 (7.6%) tweets. The average sentiment score was 0.027 ± 1.475, and neutral tweets were the most abundant (n=1,593, 38.2%). CONCLUSIONS Tweets about methylphenidate were most abundant in May, mentioned nonmedical use for study or recreation, and contained information about side effects. Analysis of Twitter has the advantage of saving the cost and time needed to conduct a survey, and could help identify nonmedical uses and side effects of drugs.

Cardiovascular, Dermatological, Gastrointestinal, Hematological, Hormonal, and Immunosuppressant Agents

2002 ◽  
Vol 37 (10) ◽  
pp. 1113-1126 ◽  
Author(s):  
Joyce A. Generali
Keyword(s):  
At Risk ◽  
Adverse Events ◽  
Drug Interactions ◽  
Prescription Drugs ◽  
Hospital Pharmacy ◽  
Safety Data ◽  
Black Box ◽  
Information Monitoring ◽  
Black Box Warnings ◽  
Wall Chart

“Black-box” warnings report valuable postmarketing safety data about prescription drugs, keeping practitioners informed about potential adverse events, drug interactions, key dosing information, monitoring and administration requirements, and at-risk patient populations. They are especially crucial for newly approved agents. A list of agents with black-box warnings does not currently exist; however Hospital Pharmacy will be publishing comprehensive lists by drug category in this column until November 2002. At that time, a complete list in wall chart form will be released. Hospital Pharmacy will update the data as salient information becomes available.

Sign in / Sign up

Export Citation Format

Share Document